News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF 28 KB

 

Not for distribution in the United States

Berlin, Germany, October 29, 2013 – Today the Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX;ISIN: DE000A1K0516) with the approval of the Supervisory Board has resolved on the increase of the Company’s share capital by EUR 660,260.00 from the authorized capital 2013/I against contribution in cash.The resolution follows a private placement of 660,260 newly issued shares with institutional investors in Europe and the U.S. Among others, the owners of Polymedco, Inc., Epigenomics’ commercialization partner in the U.S., participated in the transaction.

The issue price has been set at EUR 4.993 per share. This equals the volume-weighted average Xetra price during the period of the last three trading days before today’s date. The preemptive rights of the shareholders were excluded. Gross proceeds from this to Epigenomics amounted EUR 3.3 m. Upon registration of the capital increase with the commercial register (“Handelsregister”), the Company’s share capital will increase to EUR 12,996,387.

Epigenomics AG intends to use the net proceeds from this offering to finance its current operations and to build and strengthen the distribution capacities for its lead product Epi proColon®, a blood-based test for the detection of colorectal cancer.

-End of Ad hoc-

Disclaimer

This publication is not an offer of any securities for sale or a solicitation of an offer topurchase any securities.

This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the “Shares”) have not beenregistered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and maynot be offered or sold in the United States unless registered under the Securities Act orpursuant to an exemption from such registration. There will be no public offering of the Sharesin the United States and the Shares will not be registered under the Securities Act.

Contact:

Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.